Fujirebio Diagnostics Inc (FDI) and Randox Ltd. announced the completion of an agreement to develop cancer diagnostics assays based on Fujirebio Diagnostics' proprietary antibodies and Randox's unique automated Biochip Array technology.
Under the terms of the agreement, Fujirebio Diagnostics has provided Randox non exclusive rights to develop and commercialize a tumor marker assay panel incorporating FDI's proprietary antibodies used in the CA125II, CA19-9, CA15-3, CA72-4 and Truquant BR Tumor Marker assays on Randox's patented Biochip Array Technology. Randox will provide Fujirebio Diagnostics with payments based on future product sales.
The automated Biochip Array technology allows the simultaneous determination of a panel of diagnostic markers from a single patient sample. The markers can be used in combination or as stand-alone tests. Recent studies demonstrate that multiplexing, or combining assay determinations using the same patient sample, may improve diagnostic performance and provide more flexibility to physicians and laboratories in the future.
"We are pleased to complete this agreement with Randox and consider them to be a valuable addition to our global network of diagnostic partnerships," said Aris Petropoulos, President and Chief Operating Officer, Fujirebio Diagnostics. "The agreement with Randox is in line with our corporate strategy of being a content driven Diagnostics company and allows our standard-of-care markers to be formatted on a cutting-edge platform."